We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+34.33%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.26B
AUM Growth
+$251M
(+6.3%)
Cap. Flow
-$193M
Cap. Flow
% of AUM
-4.53%
Top 10 Holdings %
Top 10 Hldgs %
40.49%
Holding
127
New
24
Increased
16
Reduced
24
Closed
18
Avg Time Held Equity + Options
8.8
quarters
Top 10 Avg Time Held Equity + Options
7.7
quarters
Top 20 Avg Time Held Equity + Options
7.3
quarters
Avg Time Held Equity only
9.7
quarters
Top 10 Avg Time Held Equity only
7.7
quarters
Top 20 Avg Time Held Equity only
7.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Danaher
DHR
|
+$52.4M |
| 2 |
Cigna
CI
|
+$48.2M |
| 3 |
United Therapeutics
UTHR
|
+$38.6M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$29.4M |
| 5 |
Oric Pharmaceuticals
ORIC
|
+$28.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$105M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$93.6M |
| 3 |
Tenet Healthcare
THC
|
+$81.8M |
| 4 |
Boston Scientific
BSX
|
+$39.8M |
| 5 |
Cytokinetics
CYTK
|
+$35.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.63% |
| 2 | Miscellaneous | 2.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Edgewise Therapeutics
EWTX
$4.06B
| $252M | 5.92% |
15,518,492
| – | – |
2021 Q1
18 quarters
|
|
|
2
Boston Scientific
BSX
$61.9B
| $237M | 5.57% |
2,429,300
-383,900
| -14% | -$39.8M |
2014 Q1
46 quarters
|
|
3
Eli Lilly
LLY
$1.08T
| $230M | 5.4% |
301,200
-36,400
| -11% | -$27.1M |
2023 Q1
10 quarters
|
|
|
SVA
4
DELISTED
Sinovac Biotech, Ltd
SVA
| $184M | 4.33% |
2,718,735
| – | – |
2022 Q2
13 quarters
|
|
5
Enliven Therapeutics
ELVN
$2.87B
| $163M | 3.83% |
7,959,538
| – | – |
2020 Q1
22 quarters
|
|
6
Alnylam Pharmaceuticals
ALNY
$30.1B
| $138M | 3.23% |
301,600
-40,300
| -12% | -$16.4M |
2024 Q2
5 quarters
|
|
7
Stryker
SYK
$107B
| $133M | 3.12% |
359,200
| – | – |
2020 Q3
20 quarters
|
|
8
Edwards Lifesciences
EW
$49.2B
| $131M | 3.08% |
1,684,000
-24,000
| -1% | -$1.88M |
2024 Q4
3 quarters
|
|
9
Intuitive Surgical
ISRG
$147B
| $128M | 3.02% |
287,200
-3,800
| -1% | -$1.82M |
2013 Q4
47 quarters
|
|
10
argenx
ARGX
$52B
| $127M | 2.99% |
172,300
-35,700
| -17% | -$23.5M |
2022 Q1
14 quarters
|
|
11
Sionna Therapeutics
SION
$184M
| $109M | 2.56% |
3,704,959
| – | – |
2025 Q1
2 quarters
|
|
12
Upstream Bio Inc
UPB
$183M
| $107M | 2.52% |
5,693,589
| – | – |
2024 Q4
3 quarters
|
|
13
Disc Medicine
IRON
$2.18B
| $93.5M | 2.2% |
1,415,020
| – | – |
2021 Q1
18 quarters
|
|
14
Caris Life Sciences
CAI
$8.7B
| $91.8M | 2.16% |
3,034,858
| – | – |
2025 Q2
1 quarter
|
|
15
ARS Pharmaceuticals
SPRY
$395M
| $83.3M | 1.96% |
8,288,510
| – | – |
2020 Q4
19 quarters
|
|
|
RNAM
16
DELISTED
Avidity Biosciences
RNAM
| $71.4M | 1.68% |
1,638,886
-174,000
| -10% | -$7.03M |
2024 Q1
6 quarters
|
|
17
MBX Biosciences
MBX
$2.35B
| $70.1M | 1.65% |
4,002,887
| – | – |
2024 Q3
4 quarters
|
|
18
CG Oncology
CGON
$5.52B
| $69.6M | 1.63% |
1,726,850
-151,000
| -8% | -$4.39M |
2024 Q3
4 quarters
|
|
19
Natera
NTRA
$57.7B
| $69.1M | 1.62% |
429,300
-164,134
| -28% | -$26M |
2015 Q3
40 quarters
|
|
20
Axsome Therapeutics
AXSM
$8.41B
| $64.6M | 1.52% |
531,800
+103,900
| +24% | +$11.7M |
2025 Q1
2 quarters
|
|
21
DELISTED
Terns Pharmaceuticals
TERN
| $56.8M | 1.33% |
7,562,971
| – | – |
2021 Q1
18 quarters
|
|
22
ArriVent BioPharma
AVBP
$765M
| $55.9M | 1.31% |
3,027,328
| – | – |
2024 Q1
6 quarters
|
|
23
Mineralys Therapeutics
MLYS
$1.87B
| $55.7M | 1.31% |
1,469,494
+709,143
| +93% | +$15.3M |
2025 Q2
1 quarter
|
|
24
DELISTED
Exact Sciences
EXAS
| $54.4M | 1.28% |
994,616
+387,300
| +64% | +$19.4M |
2024 Q1
6 quarters
|
|
25
Compass Therapeutics
CMPX
$153M
| $53.3M | 1.25% |
15,219,994
| – | – |
2021 Q4
15 quarters
|
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q3 2025 Portfolio in Review
As of Q3 2025, OrbiMed held 127 positions worth $4.26B, up 6.3% from $4B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
OrbiMed withdrew a net $193M in Q3 2025, closing 18 positions and reducing 24 holdings. Its most notable exit was UnitedHealth, an estimated $105M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.
Against the trend, OrbiMed opened a new position in Danaher worth $52.2M.
- OrbiMed's largest Q3 2025 buy was Danaher: 263,100 shares worth $52.2M.
- OrbiMed added most to Ascendis Pharma A/S in Q3 2025, an estimated $29.4M increase.
- OrbiMed's biggest Q3 2025 reduction was Boston Scientific, cutting an estimated $39.8M.
- OrbiMed fully exited UnitedHealth in Q3 2025, selling an estimated $105M.
- OrbiMed's ten largest holdings make up 40% of its $4.26B portfolio in Q3 2025.
- OrbiMed opened 24 new positions and closed 18 in Q3 2025.
- OrbiMed's portfolio value rose 6.3% quarter-over-quarter to $4.26B.
Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.